![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Arkansas Children’s Nutrition Center, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202
3To whom correspondence should be addressed. E-mail: badgerthomasm{at}uams.edu
Infants fed soy formula are the segment of the U. S. population that consumes the most soy. Before birth and after weaning, most Americans are not exposed to appreciable levels of soyfoods other than foods that have small amounts of processed soy components. The opposite scenario occurs in Asia, because Asians are more likely to consume relatively high levels of soyfoods throughout life, except between birth and weaning, when breastfeeding or milk-based formula are common. Soy formula is made with soy protein isolate containing isoflavones (SPI+) and supports normal growth and development in term infants. Recent data suggest that there are no long-term adverse effects of early exposure to soy formula through young adulthood. It is as yet unknown whether soy formula consumption by infants will result in health problems or benefits upon aging, but multigenerational animal studies with diets made with SPI+ have not revealed any problems. Soy isoflavones can function as estrogen agonists, antagonists or selective estrogen receptor modulators, depending on the conditions, and much research has focused on health effects of purified isoflavones. Results from several studies suggest that the effects of diets made with SPI+ differ significantly from those of diets to which purified soy isoflavones are added. Furthermore, it seems that soy protein processed to contain lower levels of isoflavones also provides significant health benefits. Further research is needed to confirm the results of the few studies that have been conducted and new studies are needed to investigate the more subtle effects that could occur during development or that could surface later in life.
KEY WORDS: • soy • genistein • development • infant formula • disease prevention
This article has been cited by other articles:
|
|
 |
|
  M. J. Ronis, Y. Chen, J. Badeaux, and T. M. Badger Dietary Soy Protein Isolate Attenuates Metabolic Syndrome in Rats via Effects on PPAR, LXR, and SREBP Signaling J. Nutr., August 1, 2009; 139(8): 1431 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M Badger, J. M Gilchrist, R T. Pivik, A. Andres, K. Shankar, J.-R. Chen, and M. J Ronis The health implications of soy infant formula Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1668S - 1672S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A.L. Tan, M. Walker, K. Morris, I. Greig, J. I. Mason, and R. M. Sharpe Infant feeding with soy formula milk: effects on puberty progression, reproductive function and testicular cell numbers in marmoset monkeys in adulthood Hum. Reprod., April 1, 2006; 21(4): 896 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Ronis, Y. Chen, J. Badeaux, E. Laurenzana, and T. M. Badger Soy Protein Isolate Induces CYP3A1 and CYP3A2 in Prepubertal Rats Experimental Biology and Medicine, January 1, 2006; 231(1): 60 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ronis, Y. Chen, C.-H. Jo, P. Simpson, and T. M. Badger Diets Containing Soy Protein Isolate Increase Hepatic CYP3A Expression and Inducibility in Weanling Male Rats Exposed during Early Development J. Nutr., December 1, 2004; 134(12): 3270 - 3276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yonezawa, S. Nunomiya, M. Daigo, Y. Ogra, K. T. Suzuki, K. Enomoto, H. Nakagama, K. Yoshikawa, and M. Nagao Soy Protein Isolate Enhances Hepatic Copper Accumulation and Cell Damage in LEC Rats J. Nutr., May 1, 2003; 133(5): 1250 - 1254. [Abstract] [Full Text] [PDF]
|
|
